Related Experiment Video
Updated: Oct 13, 2026

Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay
Published on: December 19, 2018
Cis element 'decoy' against the upstream promoter of the human estrogen receptor gene
L Penolazzi1, E Lambertini, G Aguiari
1Dipartimento di Biochimica e Biologia Molecolare, Università degli Studi di Ferrara, Via L. Borsari, 46 44100, Ferrara, Italy.
Abstract:
It is well known that breast carcinomas without estrogen receptor (ER) have a poor prognosis and do not respond to endocrine therapy. In analyzing the question of the lack of ER gene expression, we have considered the possibility that specific negative transcription factors are present in ER-negative breast cancers. Inside the P3 upstream promoter of human ER gene we identified a transcriptional regulatory sequence able to bind protein factors expressed in ER-negative MDA-MB-231 breast cancer cells. This sequence, lying between nucleotides -3258 to -3157, seems to be critical for inhibition of ER gene transcription. In fact, the selected sequence in the form of double-stranded DNA has been introduced into ER-negative breast cancer cells as 'decoy' cis elements showing the ability to remove the putative negative transcription factor(s) and to induce the reactivation of ER gene transcription. In addition, in transient transfection assays the selected sequence decreased the SV-40 promoted luciferase activity. Gel shift assays identified multiple DNA-protein interactions which specifically form in this region, and data from Southwestern experiments strongly suggested the presence of a specific protein expressed in MDA-MB-231 ER-negative, but not in MCF7 ER-positive cells.
Insights
Estrogen receptor (ER)-negative breast cancers lack ER gene expression. Researchers identified a specific DNA sequence that binds negative transcription factors, inhibiting ER gene expression in these cancers.
Area of Science:
- Molecular Biology
- Oncology
- Genetics
Background:
- Estrogen receptor (ER)-negative breast carcinomas are associated with poor prognosis and resistance to endocrine therapy.
- The molecular mechanisms underlying the lack of ER gene expression in these tumors remain incompletely understood.
- Identifying factors that regulate ER gene expression is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the potential role of negative transcription factors in suppressing ER gene expression in ER-negative breast cancer cells.
- To identify specific DNA sequences within the ER gene promoter that interact with these putative negative factors.
- To explore the possibility of reactivating ER gene expression in ER-negative cells.
Main Methods:
- Analysis of the P3 upstream promoter of the human ER gene.
- Identification and characterization of a specific DNA sequence (-3258 to -3157) that binds proteins from ER-negative MDA-MB-231 cells.
- Introduction of this DNA sequence as 'decoy' cis elements into ER-negative breast cancer cells.
- Transient transfection assays using SV-40 promoted luciferase reporter.
- Gel shift assays and Southwestern experiments to identify DNA-protein interactions and specific proteins.
Main Results:
- A critical DNA sequence in the ER gene promoter (-3258 to -3157) was identified that binds protein factors present in ER-negative MDA-MB-231 cells.
- This sequence was shown to inhibit ER gene transcription.
- Introduction of the DNA sequence as a 'decoy' element reactivated ER gene transcription in ER-negative cells.
- The identified sequence decreased SV-40 promoted luciferase activity in transfection assays.
- Gel shift and Southwestern assays confirmed specific DNA-protein interactions and the presence of a protein unique to ER-negative MDA-MB-231 cells.
Conclusions:
- A novel regulatory mechanism involving negative transcription factors and a specific DNA sequence in the ER gene promoter contributes to ER gene silencing in ER-negative breast cancer.
- The identified 'decoy' cis element strategy shows potential for reactivating ER gene expression, offering a new therapeutic avenue for ER-negative breast cancers.
Related Concept Videos
The Eukaryotic Promoter Region
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Co-activators and Co-repressors
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Internal Receptors
RNA Polymerase II Accessory Proteins

